Found: 6
Select item for more details and to access through your institution.
Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS.
- Published in:
- Rheumatology, 2022, v. 61, n. 12, p. 4962, doi. 10.1093/rheumatology/keac192
- By:
- Publication type:
- Article
Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study.
- Published in:
- ACR Open Rheumatology, 2023, v. 5, n. 1, p. 28, doi. 10.1002/acr2.11512
- By:
- Publication type:
- Article
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome.
- Published in:
- Arthritis & Rheumatology, 2024, v. 76, n. 6, p. 928, doi. 10.1002/art.42801
- By:
- Publication type:
- Article
Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 8, p. 1407, doi. 10.1002/art.42489
- By:
- Publication type:
- Article
Endothelial Cell–Activating Antibodies in COVID‐19.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 7, p. 1132, doi. 10.1002/art.42094
- By:
- Publication type:
- Article
Defibrotide Inhibits Antiphospholipid Antibody–Mediated Neutrophil Extracellular Trap Formation and Venous Thrombosis.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 5, p. 902, doi. 10.1002/art.42017
- By:
- Publication type:
- Article